Thymosin Alpha-1
Thymosin Alpha-1 • Also called TA1, Thymosin Alpha 1
Thymosin Alpha-1 is followed for immune modulation and is one of the notable peptides pushed into PCAC review rather than left in Category 2 outright.
Current status
Under Review
Immune-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Removal from the Category 2 list improved sentiment, but pharmacies still wait for formal clarity.
Primary Use
Immune-related interest
Also searched as
TA1, Thymosin Alpha 1
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 19, 2024
Current status signal recorded: Referred to PCAC for further review after removal from Category 2 treatment..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Thymosin Alpha-1 status changes
State-specific notes
California
Some interest returned, but compliant access is still limited.
New York
Review status has not yet normalized availability.